Comments
The shares of Bajaj Healthcare Ltd recorded a fresh 52-week high after the company launched Ivermectin tablets for the treatment of Covid-19.
At 12:45 pm, Bajaj Healthcare was trading at ₹624.05 on the BSE, up ₹36.65 or 6.24 per cent. It touched a 52-week high of ₹625.00. It had opened at ₹586.90 as against the previous close of ₹587.40.
The company on Thursday announced the launch of “Ivejaj” (Ivermectin) an AntiParasitic Drug now widely used in control & treatment for Covid-19 patients.
Also read: Bajaj Group commits ₹200 crore to fight Covid-19
“BHL has received approval from India's drug regulator, to manufacture and market “Ivejaj” the oral Ivermectin approved medication in India for the treatment of Covid-19 from 6th May 2021,” it said in a regulatory filing.
It has successfully developed the active pharmaceutical ingredient (API) and the formulation for Ivermectin through its own in-house R&D team, it said.
The drug will be available as a prescription-based medication, with recommended doses.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.